Walleye Capital LLC Buys Shares of 166,788 Personalis, Inc. (NASDAQ:PSNL)

Walleye Capital LLC acquired a new position in Personalis, Inc. (NASDAQ:PSNL - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 166,788 shares of the company's stock, valued at approximately $897,000. Walleye Capital LLC owned 0.31% of Personalis as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in Personalis by 58.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company's stock valued at $142,000 after purchasing an additional 34,900 shares during the last quarter. ARK Investment Management LLC lifted its holdings in shares of Personalis by 4.9% during the 2nd quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company's stock valued at $7,443,000 after buying an additional 296,413 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Personalis by 6.7% in the 2nd quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company's stock valued at $1,237,000 after buying an additional 66,128 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in Personalis by 42.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock worth $81,000 after buying an additional 4,504 shares during the last quarter. Finally, nVerses Capital LLC bought a new position in Personalis during the third quarter valued at approximately $40,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Trading Up 9.8 %

PSNL traded up $0.37 during trading on Friday, hitting $4.15. The company's stock had a trading volume of 617,890 shares, compared to its average volume of 874,894. The firm's 50 day moving average price is $4.55 and its two-hundred day moving average price is $3.69. Personalis, Inc. has a 12 month low of $1.12 and a 12 month high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $25.71 million during the quarter, compared to the consensus estimate of $20.67 million. During the same quarter in the previous year, the business posted ($0.51) earnings per share. Analysts predict that Personalis, Inc. will post -1.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on PSNL. BTIG Research upped their price target on Personalis from $5.50 to $7.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. Needham & Company LLC reiterated a "buy" rating and set a $7.25 price target on shares of Personalis in a report on Thursday, November 7th. Finally, HC Wainwright lifted their price target on shares of Personalis from $7.50 to $9.00 and gave the company a "buy" rating in a research report on Monday, August 19th.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.